Mannkind, Game-Chancer in Sachen Diabetik? (Seite 222)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 10.05.24 08:11:18 von
neuester Beitrag 10.05.24 08:11:18 von
Beiträge: 6.836
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 5
Gesamt: 594.476
Gesamt: 594.476
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: NNFN
4,5180
EUR
+1,21 %
+0,0540 EUR
Letzter Kurs 10:03:19 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
08.03.24 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,2050 | +71,73 | |
| 0,5120 | +71,24 | |
| 1,2280 | +38,44 | |
| 1,2791 | +30,51 | |
| 1,8500 | +29,37 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,5900 | -29,95 | |
| 1,7000 | -31,17 | |
| 2,7050 | -41,20 | |
| 0,7280 | -46,07 | |
| 4,0200 | -64,42 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 58.049.197 von Aurum2010 am 23.06.18 00:12:53Was geht den hier ab bitte????
Hat wer eine Erklärung für den Handel....keine News und solch ein Volumen, naja, schon etwas
mysteriös, oder etwa nicht?
Hat wer eine Erklärung für den Handel....keine News und solch ein Volumen, naja, schon etwas
mysteriös, oder etwa nicht?
Heute 20 Mio. Volumen...
Warte auf den Tag mit 600+
Antwort auf Beitrag Nr.: 58.047.139 von price-of-success am 22.06.18 19:04:41DANKE FÜR DIE INFO!
Per Stock Twits, 6-15-18 Afrezza Wkly Revenue $679.k vs. $776.k, TRx 514 vs. 537, NRx 257 vs. 304, ...
Source investor village
Source investor village
Trading Spotlight
Wir brauchen geld.
Gibt es schon Zahlen? Aber eh egal der Kursverlauf spricht eh Bände!
MannKind to Host Institutional Investor and Analyst Meeting
Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes
MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes Association’s 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it will host an invitation-only luncheon at Lotte New York Palace on Wednesday, June 27, 2018 for institutional investors and analysts, also accessible by live webcast (details below). This event will feature leading endocrinologist, Steven V. Edelman, MD, University of California - San Diego, who will discuss the current and novel approaches to treatment and management of diabetes in Type 1 and Type 2 patients.
Michael Castagna, Chief Executive Officer of MannKind Corporation, will provide a corporate overview followed by MannKind’s Chief Medical Officer, David Kendall, presenting the latest Afrezza data released at the American Diabetes Association’s 78th Scientific Sessions held June 22-26, 2018. Dr. Edelman and MannKind’s management team will be available to answer questions at the conclusion of the event.
Dr. Edelman is a Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego and the Director of the Diabetes Care Clinic, VA Medical Center. Dr. Edelman has strong interests in education and patient advocacy. He is the founder and director of Taking Control of Your Diabetes (TCOYD), a not-for-profit organization with the goal of teaching and motivating patients in diabetes self-care. Dr. Edelman was recently named in US News and World Report amongst the top 1% of endocrinologists in the United States.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay will be accessible via the link here. If you would like to ask a question during the live Q&A, please submit your request via email.
Renowned Endocrinology Expert Presenting Current Trends in Treatment and Management of Diabetes
MannKind’s Chief Medical Officer Presenting New Afrezza® Data Released at American Diabetes Association’s 78th Scientific Sessions
WESTLAKE VILLAGE, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it will host an invitation-only luncheon at Lotte New York Palace on Wednesday, June 27, 2018 for institutional investors and analysts, also accessible by live webcast (details below). This event will feature leading endocrinologist, Steven V. Edelman, MD, University of California - San Diego, who will discuss the current and novel approaches to treatment and management of diabetes in Type 1 and Type 2 patients.
Michael Castagna, Chief Executive Officer of MannKind Corporation, will provide a corporate overview followed by MannKind’s Chief Medical Officer, David Kendall, presenting the latest Afrezza data released at the American Diabetes Association’s 78th Scientific Sessions held June 22-26, 2018. Dr. Edelman and MannKind’s management team will be available to answer questions at the conclusion of the event.
Dr. Edelman is a Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego and the Director of the Diabetes Care Clinic, VA Medical Center. Dr. Edelman has strong interests in education and patient advocacy. He is the founder and director of Taking Control of Your Diabetes (TCOYD), a not-for-profit organization with the goal of teaching and motivating patients in diabetes self-care. Dr. Edelman was recently named in US News and World Report amongst the top 1% of endocrinologists in the United States.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay will be accessible via the link here. If you would like to ask a question during the live Q&A, please submit your request via email.
Antwort auf Beitrag Nr.: 58.018.192 von questionmark am 19.06.18 14:58:10Weiß leider nicht wie das geht, aber bei Mannkind Finanznachrichten ein Bericht von Seeking Alpha.
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
